<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28390791</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1555-7162</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>130</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>The American journal of medicine</Title>
          <ISOAbbreviation>Am J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?</ArticleTitle>
        <Pagination>
          <StartPage>900</StartPage>
          <EndPage>906</EndPage>
          <MedlinePgn>900-906</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjmed.2017.02.048</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0002-9343(17)30342-X</ELocationID>
        <Abstract>
          <AbstractText>Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the US Food and Drug Administration for treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Similar to other DOACs, edoxaban has fewer drug-drug interactions than warfarin and does not require routine laboratory monitoring. Unlike other DOACs, edoxaban has yet to be approved for secondary or postoperative venous thromboembolism thromboprophylaxis. Currently no antidote for edoxaban is available. To optimally prescribe agents in the DOAC class, it is critical that providers 1) understand how the agents compare; and 2) identify specific settings in which one agent may be preferred over another.</AbstractText>
          <CopyrightInformation>Copyright Â© 2017 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gibson</LastName>
            <ForeName>Caitlin M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>University of North Texas System College of Pharmacy, Fort Worth. Electronic address: Caitlin.gibson@unthsc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Finks</LastName>
            <ForeName>Shannon W</ForeName>
            <Initials>SW</Initials>
            <AffiliationInfo>
              <Affiliation>University of Tennessee College of Pharmacy, Memphis.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>04</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Am J Med</MedlineTA>
        <NlmUniqueID>0267200</NlmUniqueID>
        <ISSNLinking>0002-9343</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NDU3J18APO</RegistryNumber>
          <NameOfSubstance UI="C552171">edoxaban</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Anticoagulation</Keyword>
        <Keyword MajorTopicYN="Y">Atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="Y">Direct oral anticoagulant</Keyword>
        <Keyword MajorTopicYN="Y">Edoxaban</Keyword>
        <Keyword MajorTopicYN="Y">Factor Xa inhibitors</Keyword>
        <Keyword MajorTopicYN="Y">Venous thromboembolism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28390791</ArticleId>
        <ArticleId IdType="doi">10.1016/j.amjmed.2017.02.048</ArticleId>
        <ArticleId IdType="pii">S0002-9343(17)30342-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
